Phytocannabinoids and endocannabinoids

Current Drug Abuse Reviews

Volumn 2, Issue 1, 2009, Pages 51-75

  Fišar, Zdeněk ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Addiction; Arachidonic acid; Cannabis; Endocannabinoids; Membranes; Mental disorders; Receptors; Synthetic cannabinoids

Indexed keywords

ANTINEOPLASTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DRONABINOL; ENDOCANNABINOID; FATTY ACID DERIVATIVE; ILLICIT DRUG; LIPID; NABILONE; NEUROTRANSMITTER; PHYTOCANNABINOID; PSYCHOTROPIC AGENT; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; CANNABINOID;

ACUTE TOXICITY; ANOREXIA; ARTICLE; ASTHMA; BIOCHEMISTRY; BIOSYNTHESIS; CACHEXIA; CANNABIS ADDICTION; CANNABIS SMOKING; CELL MEMBRANE; CLINICAL TRIAL; COGNITION; DEGENERATIVE DISEASE; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG MECHANISM; DYSTONIA; EMOTIONALITY; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HUMAN; INTOXICATION; LIPID MEMBRANE; MEMORY DISORDER; MENTAL DISEASE; METABOLITE; MOTOR DYSFUNCTION; NAUSEA; NAUSEA AND VOMITING; NERVE CELL; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NEUROTRANSMITTER RELEASE; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; PSYCHOSIS; SCHIZOPHRENIA; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; SPASTICITY; STRUCTURE ACTIVITY RELATION; TARDIVE DYSKINESIA; TOXICOKINETICS; TREMOR; UNSPECIFIED SIDE EFFECT; ANIMAL; CHEMISTRY; DRUG EFFECT; MEDICINAL PLANT; METABOLISM; PHYSIOLOGY; REVIEW;

ANIMALS; CANNABINOIDS; CANNABIS; ENDOCANNABINOIDS; HUMANS; PLANTS, MEDICINAL; RECEPTORS, CANNABINOID; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57449118210     PISSN: 18744737     EISSN: None     Source Type: Journal    
DOI: 10.2174/1874473710902010051     Document Type: Article

References (296)

1. Earleywine M. Understanding marijuana: a new look at the scientific evidence. New York, Oxford University Press 2002.
2. Koob GF, Le Moal M. Neurobiology of addiction. Elsevier 2006; 289-337.
3. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 2007; 4: 1614-48.
4. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
5. Mechoulam R, Gaoni Y. A total synthesis of dl-1-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 1965; 87: 3273-5.
6. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-13.
7. Devane WA, Hanu L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258: 1946-9.
8. Mechoulam R, Ben-Shabat S, Hanu L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
9. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161-202.
10. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48: 5059-87.
11. Challapalli PV, Stinchcomb AL. In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm 2002; 241: 329-39.
12. Clarke RC, Watson DP. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 3-13.
13. ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78: 539-48.
14. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 2007; 152: 583-93.
15. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613-23.
16. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-46.
17. Herman TS, Jones SE, Dean J, et al. Nabilone: a potent antiemetic cannabinol with minimal euphoria. Biomedicine 1977; 27: 331-4.
18. Davis WM, Hatoum NS. Neurobehavioral actions of cannabichromene and interactions with delta 9-tetrahydrocannabinol. Gen Pharmacol 1983; 14: 247-52.
19. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 2005; 16: 487-96.
20. Grotenhermen F. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 55-65.
21. Pacher P, Bátkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 2005; (168): 599-625.
22. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol 2004; 88: 708-13.
23. Savinainen JR, Laitinen JT. Detection of cannabinoid CB1, adenosine A1, muscarinic acetylcholine, and GABAB receptor-dependent G protein activity in transducin-deactivated membranes and autoradiography sections of rat retina. Cell Mol Neurobiol 2004; 24: 243-56.
24. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
25. World Health Organization: Cannabis: a health perspective and research agenda. Division of mental health and prevention of substance abuse: WHO 1997.
26. Solowij N. Cannabis and Cognitive Funtioning. Cambridge, Cambridge University Press 1998.
27. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337-43.
28. Solowij N, Michie PT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 2007; 32: 30-52.
29. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909-15.
30. Russo E, Mathre ML, Byrne A, et al. Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther 2002; 2: 3-57.
31. Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Nonacute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9: 679-89.
32. Paton WD. Pharmacology of marijuana. Annu Rev Pharmacol 1975; 15: 191-220.
33. Leuschner JT, Wing DR, Harvey DJ, et al. The partitioning of delta 1-tetrahydrocannabinol into erythrocyte membranes in vivo and its effect on membrane fluidity. Experientia 1984; 40: 866-8.
34. Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998; 38: 179-200.
35. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 101-21.
36. Mackie K. Understanding cannabinoid psychoactivity with mouse genetic models. PLoS Biol 2007; 5: e280.
37. Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl) 2003; 169: 115-34.
38. Elphick MR, Egertová M. The neurobiology and evolution of cannabinoid signalling. Phil Trans R Soc Lond B Biol Sci 2001; 356: 381-408.
39. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
40. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999; 58: 315-48.
41. Velenovská M, Fišar Z. Effect of cannabinoids on platelet serotonin uptake. Addict Biol 2007; 12: 158-66.
42. Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of 9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 2007; 555: 156-63.
43. Walter L, Stella N. Cannabinoids and neuroinflammation. Br J Pharmacol 2004; 141: 775-85.
44. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310: 329-32.
45. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87: 1932-6.
46. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-83.
47. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83: 1017-66.
48. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 2000; 396: 141-9.
49. Ibrahim MM, Rude ML, Stagg NJ, et al. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36-42.
50. Gertsch J, Schoop R, Kuenzle U, Suter A. Echinacea alkylamides modulate TNF-gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett 2004; 577: 563-9.
51. Raduner S, Majewska A, Chen J-Z, et al. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. J Biol Chem 2006; 281: 14192-206.
52. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16: 276-82.
53. Grotenhermen F. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 345-53.
54. Favrat B, Ménétrey A, Augsburger M, et al. Two cases of cannabis acute psychosis following the administration of oral cannabis. BMC Psychiatry 2005; 5: 17.
55. Cone EJ, Huestis MA. Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit 1993; 15: 527-32.
56. Naef M, Russmann S, Petersen-Felix S, Brenneisen R. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 2004; 93: 1176-84.
57. Iversen LL. The Science of Marijuana. New York, Oxford University Press 2000.
58. Brenneisen R. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 67-72.
59. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215: 89-97.
60. Hanu L, Abu-Lafi S, Fride E, et al. 2-Arachidonyl glycerol ether, a novel endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98: 3662-5.
61. Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301: 1020-4.
62. Huang SM, Bisogno T, Trevisani M, et al. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002; 99: 8400-5.
63. Hanu L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993; 36: 3032-4.
64. Barg J, Fride E, Hanus L, et al. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur J Pharmacol 1995; 287: 145-52.
65. Walker JM, Krey JF, Chu CJ, Huang SM. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 2002; 121: 159-72.
66. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996; 393: 231-5.
67. Bazinet RP, Lee HJ, Felder CC, Porter AC, Rapoport SI, Rosenberger TA. Rapid high-energy microwave fixation is required to determine the anandamide (N-arachidonoylethanolamine) concentration of rat brain. Neurochem Res 2005; 30: 597-601.
68. Maccarrone M, Bari M, Finazzi-Agrò A. Quantification of anandamide content in animal cells and tissues: the normalization makes the difference. Lipids Health Dis 2002; 1: 4.
69. Muccioli GG, Stella N. An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. Anal Biochem 2008; 373: 220-8.
70. Hillard CJ, Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 2000; 108: 123-34.
71. Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003; 140: 802-8.
72. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997; 388: 773-8.
73. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993; 231: 313-4.
74. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270: 219-27.
75. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998; 284: 1209-17.
76. Wiley JL, Ryan WJ, Razdan RK, Martin BR. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats. Eur J Pharmacol 1998; 355: 113-8.
77. Solinas M, Tanda G, Justinova Z, et al. The endogenous cannabinoid anandamide produces δ-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 2007; 321: 370-80.
78. Bodor AL, Katona I, Nyíri G, et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. J Neurosci 2005; 25: 6845-56.
79. Nyíri G, Cserép C, Szabadits E, Mackie K, Freund TF. CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 2005; 136: 811-22.
80. Maejima T, Ohno-Shosaku T, Kano M. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neurosci Res 2001; 40: 205-10.
81. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47(Suppl 1): 345-58.
82. Kreitzer AC, Regehr WG. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol 2002; 12: 324-30.
83. Brown TM, Brotchie JM, Fitzjohn SM. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 2003; 23: 11073-7.
84. Shivachar AC. Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes. Biochem Pharmacol 2007; 73: 2004-11.
85. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-84.
86. Chevaleyre V, Takahashi KA, Castillo PE. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 2006; 29: 37-76.
87. Chevaleyre V, Heifets BD, Kaeser PS, Südhof TC, Castillo PE. Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1α. Neuron 2007; 54: 801-12.
88. Mackie K. From active ingredients to the discovery of the targets: the cannabinoid receptors. Chem Biodivers 2007; 4: 1693-706.
89. Hashimotodani Y, Ohno-Shosaku T, Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007; 13: 127-37.
90. Lovinger DM. Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol 2008; (184): 435-77.
91. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
92. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1545-64.
93. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 2006; 69: 691-6.
94. Hampson AJ, Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 2001; 13: 1529-36.
95. Butovsky E, Juknat A, Goncharov I, et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to 9-tetrahydrocannabinol. J Neurochem 2005; 93: 802-11.
96. Tasker JG. Rapid glucocorticoid actions in the hypothalamus as a mechanism of homeostatic integration. Obesity (Silver Spring) 2006; 14(Suppl 5): 259S-265S.
97. Marsicano G, Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 2006; 29(3 Suppl): 27-46.
98. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
99. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007; 114: 13-33.
100. Beardsley PM, Thomas BF. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behav Pharmacol 2005; 16: 275-96.
101. Hampson A. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 101-9.
102. Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75: 2434-44.
103. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006; 8: E298-306.
104. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60: 155-63.
105. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27(1): 1-4.
106. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007; 152: 567-75.
107. Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152: 1092-101.
108. Jiang WG, Bryce RP, Horrobin DF. Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. Crit Rev Oncol/Hematol 1998; 27: 179-209.
109. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J Neurosci 2001; 21(RC188): 1-5.
110. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidyle-thanolamine, in rat brain. J Neurosci 1997; 17: 1226-42.
111. Hansen HH, Hansen SH, Schousboe A, Hansen HS. Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J Neurochem 2000; 75: 861-71.
112. Schmid HH. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem Phys Lipids 2000; 108: 71-87.
113. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006; 45: 4720-6.
114. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for α/β-hydrolase 4 in this pathway. J Biol Chem 2006; 281: 26465-72.
115. Liu J, Wang L, Harvey-White J, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 2006; 103: 13345-50.
116. Liu J, Wang L, Harvey-White J, et al. Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 2008; 54: 1-7.
117. Sun Y-X, Tsuboi K, Okamoto Y, et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J 2004; 380: 749-56.
118. Shetty HU, Smith QR, Washizaki K, Rapoport SI, Purdon AD. Identification of two molecular species of rat brain phosphatidylcholine that rapidly incorporate and turn over arachidonic acid in vivo. J Neurochem 1996; 67: 1702-10.
119. Sugiura T, Kondo S, Sukagawa A, et al. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur J Biochem 1996; 240: 53-62.
120. Hiroyama M, Takenawa T. Purification and characterization of a lysophosphatidic acid-specific phosphatase. Biochem J 1998; 336: 483-9.
121. Nakane S, Oka S, Arai S, et al. 2-Arachidonoyl-sn-glycero-3-phosphate, an arachidonic acid-containing lysophosphatidic acid: occurrence and rapid enzymatic conversion to 2-arachidonoyl-snglycerol, a cannabinoid receptor ligand, in rat brain. Arch Biochem Biophys 2002; 402: 51-8.
122. Glaser ST, Kaczocha M, Deutsch DG. Anandamide transport: a critical review. Life Sci 2005; 77: 1584-604.
123. Fowler CJ. The cannabinoid system and its pharmacological manipulation-a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 2006; 20: 549-62.
124. Fowler CJ. The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br J Pharmacol 2007; 152: 594-601.
125. Hermann A, Kaczocha M, Deutsch DG. 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPS J 2006; 8: E409-12.
126. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002; 121: 149-58.
127. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 2007; 14: 1347-56.
128. Muccioli GG, Xu C, Odah E, et al. Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. J Neurosci 2007; 27: 2883-9.
129. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003; 7: 469-75.
130. Di Marzo V, Cristino L. Why endocannabinoids are not all alike. Nat Neurosci 2008; 11: 124-6.
131. Maccarrone M, Rossi S, Bari M, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008; 11: 152-9.
132. Palmer SL, Thakur GA, Makriyannis A. Cannabinergic ligands. Chem Phys Lipids 2002; 121: 3-19.
133. Huffman JW, Bushell SM, Joshi SN, Wiley JL, Martin BR. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. Bioorg Med Chem 2006; 14: 247-62.
134. Brizzi A, Cascio MG, Brizzi V, et al. Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. Bioorg Med Chem 2007; 15: 5406-16.
135. Marriott KS, Huffman JW. Recent advances in the development of selective ligands for the cannabinoid CB2 receptor. Curr Top Med Chem 2008; 8: 187-204.
136. Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993; 265: 218-26.
137. Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277: 586-94.
138. D'Ambra TE, Estep KG, Bell MR, et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J Med Chem 1992; 35: 124-35.
139. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
140. Goutopoulos A, Fan P, Khanolkar AD, Xie X-Q, Lin S, Makriyannis A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg Med Chem 2001; 9: 1673-84.
141. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240-4.
142. Rinaldi-Carmona M, Barth F, Congy C, et al. SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004; 310: 905-14.
143. Felder CC, Joyce KE, Briley EM, et al. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther 1998; 284: 291-7.
144. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther 1998; 284: 644-50.
145. Pertwee R, Griffin G, Fernando S, Li X, Hill A, Makriyannis A. AM630, a competitive cannabinoid receptor antagonist. Life Sci 1995; 56: 1949-55.
146. Herbette LG, Chester DW, Rhodes DG. Structural analysis of drug molecules in biological membranes. Biophys J 1986; 49: 91-4.
147. Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991; 34: 869-77.
148. Seydel JK, Velasco MA, Coats EA, Cordes HP, Kunz B, Wiese M. The importance of drug-membrane interaction in drug research and development. Quant Struct-Act Relat 1992; 11: 205-10.
149. Fišar Z. Fytokanabinoidy. Chem Listy 2006; 100: 233-42.
150. Fišar Z. Endokanabinoidy. Chem Listy 2006; 100: 314-22.
151. Dainese E, Oddi S, Bari M, Maccarrone M. Modulation of the endocannabinoid system by lipid rafts. Curr Med Chem 2007; 14: 2702-15.
152. Shinitzky M. In: Kates M, Manson LA, Eds, Membrane Fluidity. New York, Plenum Publishing Corporation 1984; 585-601.
153. Srivastava LK, Kazmi SM, Blume AJ, Mishra RK. Reconstitution of affinity-purified dopamine D2 receptor binding activities by specific lipids. Biochim Biophys Acta 1987; 900: 175-82.
154. Scanlon SM, Williams DC, Schloss P. Membrane cholesterol modulates serotonin transporter activity. Biochemistry 2001; 40: 10507-13.
155. Cornelius F. Modulation of Na,K-ATPase and Na-ATPase activity by phospholipids and cholesterol. I. Steady-state kinetics. Biochemistry 2001; 40: 8842-51.
156. Lee AG. Lipid-protein interactions in biological membranes: a structural perspective. Biochim Biophys Acta 2003; 1612: 1-40.
157. Fišar Z, Anders M, Kališová L. Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys 2005; 24: 113-28.
158. Fišar Z, Anders M, Tvrzická E, Staňková B. Effect of long-term administration of antidepressants on the lipid composition of brain plasma membranes. Gen Physiol Biophys 2005; 24: 221-36.
159. Vevera J, Fišar Z, Kvasniška T, et al. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res 2005; 133: 197-203.
160. Barenholz Y. Cholesterol and other membrane active sterols: from membrane evolution to rafts. Prog Lipid Res 2002; 41: 1-5.
161. Fielding CJ, Fielding PE. Relationship between cholesterol trafficking and signaling in rafts and caveolae. Biochim Biophys Acta 2003; 1610: 219-28.
162. Pike LJ, Han X, Chung K-N, Gross RW. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry 2002; 41: 2075-88.
163. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 2004; 378(Pt 2): 281-92.
164. Hořejší V. Lipid rafts and their roles in T-cell activation. Microbes Infect 2005; 7: 310-6.
165. Barnett-Norris J, Lynch D, Reggio PH. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci 2005; 77: 1625-39.
166. Langner M, Kubica K. The electrostatics of lipid surfaces. Chem Phys Lipids 1999; 101: 3-35.
167. Dumas F, Lebrun MC, Tocanne J-F. Is the protein/lipid hydrophobic matching principle relevant to membrane organization and functions? FEBS Lett 1999; 458: 271-7.
168. Hurley JH, Tsujishita Y, Pearson MA. Floundering about at cell membranes: a structural view of phospholipid signaling. Curr Opin Struct Biol 2000; 10: 737-43.
169. Marsh D. Lipid-binding proteins: Structure of the phospholipid ligands. Protein Sci 2003; 12: 2109-17.
170. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
171. Hibbeln JR, Salem N Jr. Dietary polyunsaturated fatty acids and depression: When cholesterol does not satisfy. Am J Clin Nutr 1995; 62: 1-9.
172. Das UN, Vaddadi KS. Essential fatty acids in Huntington's disease. Nutrition 2004; 20: 942-7.
173. Kim YJ, Takahashi R. Role of polyunsaturated fatty acids for misfolding protein aggregations: implication for neurodegenerative diseases. Ann N Y Acad Sci 2006; 1086: 11-20.
174. Biswas KK, Sarker KP, Abeyama K, et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003; 38: 1167-77.
175. Bari M, Paradisi A, Pasquariello N, Maccarrone M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J Neurosci Res 2005; 81: 275-83.
176. Bari M, Spagnuolo P, Fezza F, et al. Effect of lipid rafts on Cb2 receptor signaling and 2-arachidonoyl-glycerol metabolism in human immune cells. J Immunol 2006; 177: 4971-80.
177. Fišar Z, Fuksová K, Velenovská M. Binding of imipramine to phospholipid bilayers using radioligand binding assay. Gen Physiol Biophys 2004; 23: 77-99.
178. Fišar Z. Interactions between tricyclic antidepressants and phospholipid bilayer membranes. Gen Physiol Biophys 2005; 24: 161-80.
179. Sheskin T, Hanu L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem 1997; 40: 659-67.
180. Reggio PH, Traore H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids 2000; 108: 15-35.
181. Suhara Y, Oka S, Kittaka A, Takayama H, Waku K, Sugiura T. Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorg Med Chem 2007; 15: 854-67.
182. Rabinovich AL, Ripatti PO. On the conformational, physical properties and functions of polyunsaturated acyl chains. Biochim Biophys Acta 1991; 1085: 53-62.
183. Barnett-Norris J, Guarnieri F, Hurst DP, Reggio PH. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. J Med Chem 1998; 41: 4861-72.
184. Berglund BA, Boring DL, Wilken GH, Makriyannis A, Howlett AC, Lin S. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins Leukot Essent Fatty Acids 1998; 59: 111-8.
185. Thomas BF, Adams IB, Mascarella SW, Martin BR, Razdan RK. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J Med Chem 1996; 39: 471-9.
186. Tong W, Collantes ER, Welsh WJ, Berglund BA, Howlett AC. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J Med Chem 1998; 41: 4207-15.
187. Mechoulam R, Hanu L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 2001; 6: 67-73.
188. Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem 2008; 8: 205-30.
189. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev 2003; 22: 453-60.
190. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common? 1 opioid receptor mechanism. Science 1997; 276: 2048-50.
191. Leweke FM. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 249-56.
192. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611-6.
193. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007; 4: 1744-69.
194. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004; 142: 20-6.
195. Mendizábal VE, Adler-Graschinsky E. Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 2007; 151: 427-40.
196. Pacher P, Haskó G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2008; 153: 252-62.
197. Mathew RJ, Wilson WH, Turkington TG, et al. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res 2002; 116: 173-85.
198. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrado TR, Coleman RE. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 1999; 100: 67-75.
199. Mathew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res 1998; 797: 183-9.
200. Volkow ND, Gillespie H, Mullani N, et al. Cerebellar metabolic activation by delta9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose. Psychiatry Res 1991; 40: 69-78.
201. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-70.
202. Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend 2003; 69: 303-10.
203. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369: 1047-53.
204. Aldington S, Williams M, Nowitz M, et al. Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007; 62: 1058-63.
205. Roth MD. Pharmacology: marijuana and your heart. Nature 2005; 434: 708-9.
206. Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O. Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and 9-tetrahydrocannabinol. Am J Respir Cell Mol Biol 2001; 24: 339-44.
207. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005; 63: 93-100.
208. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1829-34.
209. Aldington S, Harwood M, Cox B, et al., Cannabis and Respiratory Disease Research Group. Cannabis use and cancer of the head and neck: case-control study. Otolaryngol Head Neck Surg 2008; 138: 374-80.
210. Aldington S, Harwood M, Cox B, et al., Cannabis and Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case-control study. Eur Respir J 2008; 31: 280-6.
211. Solowij N, Stephens RS, Roffman RA, et al. for the Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 2287: 1123-31.
212. Grotenhermen F. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 233-47.
213. Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth 1999; 83: 637-49.
214. Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend 2001; 64: 319-27.
215. Kandel DB. Does marijuana use cause the use of other drugs? JAMA 2003; 289: 482-3.
216. Gruber AJ, Pope HG Jr. Marijuana use among adolescents. Pediatr Clin North Am 2002; 49: 389-413.
217. Block RI, O'Leary DS, Ehrhardt JC, et al. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000; 11: 491-6.
218. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis 2000; 19: 1-22.
219. Matochik JA, Eldreth DA, Cadet J-L, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 2005; 77: 23-30.
220. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 2008; 1: 81-98.
221. Hermann D, Sartorius A, Welzel H, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry 2007; 61: 1281-9.
222. Schweinsburg AD, Brown SA, Tarpet SF. The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev 2008; 1: 99-111.
223. Perkonigg A, Goodwin RD, Fiedler A, et al. The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 2008; 103: 439-49.
224. Murphy LL. In: Grotenhermen F, Russo E, Eds. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 289-97.
225. Habayeb OM, Taylor AH, Evans MD, et al. Plasma levels of the endocannabinoid anandamide in women-a potential role in pregnancy maintenance and labor? J Clin Endocrinol Metab 2004; 89: 5482-7.
226. Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ 2002; 166: 887-91.
227. Goldschmidt L, Richardson GA, Willford J, Day NL. Prenatal marijuana exposure and intelligence test performance at age 6. J Am Acad Child Adolesc Psychiatry 2008; 47: 254-63.
228. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol 2002; 24: 309-20.
229. Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007; 145: 323-34.
230. Luk T, Jin W, Zvonok A, et al. Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 2004; 142: 495-500.
231. Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161: 1967-77.
232. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19: 233-8.
233. Goodman A. Neurobiology of addiction. An integrative review. Biochem Pharmacol 2008; 75: 266-322.
234. Koob G, Kreek MJ. Stress, dysregulation of drug reward pathways, and the transition to drug dependence. Am J Psychiatry 2007; 164: 1149-59.
235. Valverde O. Participation of the cannabinoid system in the regulation of emotional-like behaviour. Curr Pharm Des 2005; 11: 3421-9.
236. Rademacher DJ, Hillard CJ. Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 633-41.
237. Scherma M, Medalie J, Fratta W, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008; 54: 129-40.
238. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 2006; 29: 565-98.
239. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-9.
240. Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-15.
241. Haller J, Mátyás F, Soproni K, et al. Correlated species differences in the effects of cannabinoid ligands on anxiety and on GABAergic and glutamatergic synaptic transmission. Eur J Neurosci 2007; 25: 2445-56.
242. Maldonado R, Valverde O, Berrendero F. Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29: 225-32.
243. Wagner FA, Anthony JC. From first drug use to drug dependence; developmental periods of risk for dependence upon marijuana, cocaine, and alcohol. Neuropsychopharmacology 2002; 26: 479-88.
244. Fergusson DM, Horwood LJ, Lynskey MT, Madden PA. Early reactions to cannabis predict later dependence. Arch Gen Psychiatry 2003; 60: 1033-9.
245. von Sydow K, Lieb R, Pfister H, Höfler M, Wittchen H-U. What predicts incident use of cannabis and progression to abuse and dependence? A 4-year prospective examination of risk factors in a community sample of adolescents and young adults. Drug Alcohol Depend 2002; 68: 49-64.
246. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007; 16: 331-42.
247. Centonze D, Finazzi-Agrò A, Bernardi G, Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 2007; 28: 180-7.
248. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78: 289-326.
249. Maccarrone M, Battista N, Centonze D. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 2007; 81: 349-79.
250. Viveros M-P, Marco E-M, Llorente R, López-Gallardo M. Endocannabinoid system and synaptic plasticity: implications for emotional responses. Neural Plast 2007; 2007(52908): 1-12.
251. Mangieri RA, Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res 2007; 56: 360-6.
252. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325: 1195-8.
253. Degenhardt L, Hall W, Lynskey M. Exploring the association between cannabis use and depression. Addiction 2003; 98: 1493-504.
254. Denson TF, Earleywine M. Decreased depression in marijuana users. Addict Behav 2006; 31: 738-42.
255. Koethe D, Llenos IC, Dulay JR, et al. Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm 2007; 114: 1055-63.
256. Leweke FM, Giuffrida A, Koethe D, et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007; 94: 29-36.
257. Fišar Z, Kališová L, Paclt I, Anders M, Vevera J. Platelet serotonin uptake in drug-naïve depressive patients before and after treatment with citalopram. Psychiatry Res 2008; in press.
258. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319-28.
259. Macleod J, Oakes R, Copello A, et al. Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies. Lancet 2004; 363:1579-88.
260. Macleod J, Davey Smith G, Hickman M. Does cannabis use cause schizophrenia? Lancet 2006; 367: 1055.
261. Macleod J, Smith G, Hickman M, Egger M. Cannabis and psychosis. Lancet 2007; 370: 1539.
262. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001; 178: 116-22.
263. Degenhardt L, Hall W. Cannabis and psychosis. Curr Psychiatry Rep 2002; 4: 191-6.
264. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-3.
265. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199-201.
266. Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004; 99: 1333-41.
267. Degenhardt L, Hall W. Is cannabis use a contributory cause of psychosis? Can J Psychiatry 2006; 51: 556-65.
268. Laviolette SR, Grace AA. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 2006; 63: 1597-613.
269. Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 56: 803-7.
270. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004; 96: 376-81.
271. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7: 515-18.
272. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10: 1665-9.
273. Sarafian TA, Kouyoumjian S, Khoshaghideh F, Tashkin DP, Roth MD. Delta 9-tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung Cell Mol Physiol 2003; 284: L298-L306.
274. Sarafian TA, Habib N, Oldham M, et al. Inhaled marijuana smoke disrupts mitochondrial energetics in pulmonary epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1202-9.
275. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 2002; 83: 1241-51.
276. Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005; 10: 900-19.
277. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
278. Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005; 26: 631-8.
279. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005; 115: 3104-16.
280. Piomelli D, Giuffrida A, Calignano A, Rodríguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000; 21: 218-24.
281. Grotenhermen F. In: Grotenhermen F, Russo E, Eds, Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. New York, The Haworth Integrative Healing Press 2002; 123-42.
282. Goutopoulos A, Makriyannis A. From cannabis to cannabinergics: new therapeutic opportunities. Pharmacol Ther 2002; 95: 103-17.
283. Fowler CJ. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Rev 2003; 41: 26-43.
284. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol 2005; 19: 293-300.
285. 9-Tetrahydrocannabinol protects hippocampal neurons from excitotoxicity. Brain Res 2007; 1128: 61-9.
286. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003; 17: 179-202.
287. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006; 7: 607-15.
288. Zajicek J, Fox P, Sanders H, et al., UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
289. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-6.
290. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
291. Perras C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol 2005; (72): 1-4.
292. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29: 2068-79.
293. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; doi:10.1136/bmj.38149.566979.AE: 1-8.
294. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007; 133: 210-20.
295. Russo EB, Guy GW, Robson PJ. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers 2007; 4: 1729-43.
296. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol Lett 2004; 25: 31-9.